After a solid run for the drug giant, near-term headwinds may not allow for meaningful multiple expansion in 2019, according to one team of analysts.
from rss_headline https://ift.tt/2znI2PC
via IFTTT
from rss_headline https://ift.tt/2znI2PC
via IFTTT
Kommentare
Kommentar veröffentlichen